Elizabeth R. Plimack, MD, MS, FASCO

Articles

Key Takeaways on Updates in Bladder Cancer

April 1st 2024

Elizabeth Plimack, MD, MS, FASCO, recaps the discussion with key takeaways on recent updates in bladder cancer.

Exciting New Approaches in Metastatic Urothelial Carcinoma

March 25th 2024

Experts on bladder cancer discuss exciting new agents and treatment strategies and where they can potentially fit into urothelial cancer treatment paradigms.

Treatment Sequencing Practices in Metastatic Urothelial Carcinoma

March 25th 2024

Focusing on metastatic urothelial carcinoma, the panel discusses the role of chemotherapy and outlines treatment sequencing approaches.

Later-Line Therapies for Metastatic Urothelial Carcinoma

March 18th 2024

Evan Y. Yu, MD, provides insights on treatment approaches for patients with metastatic urothelial carcinoma in the second line and beyond.

Cisplatin Eligibility and Maintenance Therapy in Metastatic Urothelial Carcinoma

March 18th 2024

The expert panel discusses how treatment strategies change based on cisplatin eligibility and the role of maintenance therapy in metastatic urothelial carcinoma.

Clinical Insights on Recent Data in Metastatic Urothelial Carcinoma

March 11th 2024

GU medical oncologists offer their impressions of recent updates in the metastatic urothelial carcinoma space, focusing on CheckMate 901 and EV-302.

Emerging Data in Metastatic Urothelial Carcinoma

March 11th 2024

Neeraj Agarwal, MD, FASCO, provides a comprehensive overview of recent data in metastatic urothelial carcinoma, highlighting the CheckMate 901 and EV-302 studies.

Expert Insights on Updates in Adjuvant Therapy for Muscle-Invasive Bladder Cancer

March 4th 2024

Experts on muscle-invasive bladder cancer respond to recent data in adjuvant therapy that were presented at ASCO GU 2024.

Recent Updates in Adjuvant Therapy for Muscle-Invasive Bladder Cancer

March 4th 2024

Following an overview of the evolving adjuvant therapy space, Matthew Milowsky, MD, FASCO, reviews recent updates from ASCO GU 2024 in muscle-invasive bladder cancer.

Ongoing Research on Neoadjuvant Therapies in Muscle-Invasive Bladder Cancer

February 26th 2024

Focusing on neoadjuvant therapy, the expert panel discusses ongoing clinical research in muscle-invasive bladder cancer and the potential role of novel strategies in the treatment space.

Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer (MIBC)

February 26th 2024

A panel of experts on bladder cancer introduce themselves and give an overview of the neoadjuvant therapy landscape for patients with muscle-invasive bladder cancer.

Future Perspectives in the Treatment of Advanced RCC

November 3rd 2023

Oncologists discuss the need for more data on treatment duration in advanced RCC, emphasize the value of long-term patient follow-ups, and highlight the translational focus of the KCRS annual meeting, which combines clinical and early-stage research for renal cell carcinoma.

Dr. Plimack on Updated Findings of the KEYNOTE-426 Study in RCC

June 2nd 2020

Elizabeth R. Plimack, MD, MS, discusses the updated findings from the phase 3 KEYNOTE-426 study in patients with previously untreated, advanced renal cell carcinoma.